Payment overview · 2025
General Payments
$1,576.25
56 reported records · 16 companies
Healthcare provider profile · identity verified
Edward James Arias, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · SACRAMENTO, CA · NPI 1922018993
Verified facts
What the public records show
CMS Open Payments records show Edward James Arias, PA received $1,576.25 in general payments during 2025 across 56 reported records.
Neurocrine BioSciences, Inc. accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $456.73 | 29.0% | 7 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $298.64 | 18.9% | 19 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $137.54 | 8.7% | 6 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $121.84 | 7.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $111.87 | 7.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $107.05 | 6.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.40 | 3.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.01 | 3.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.13 | 3.0% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$34.93 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.71 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.29 | 1.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.14 | 1.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $26.12 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.53 | 1.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.32 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,576.25 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $298.64 | 19 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $142.58 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $137.54 | 6 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $137.54 | 6 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $82.29 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $81.28 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.01 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.13 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $28.14 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 622 | 117 |
| Gabapentin | Gabapentin | 377 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 367 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 48 |
| Lisinopril | Lisinopril | 219 | 75 |
| Metformin Hcl | Metformin Hcl | 213 | 79 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 189 | 31 |
| Azelastine Hcl | Azelastine Hcl | 172 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 54 |
| Losartan Potassium | Losartan Potassium | 158 | 64 |
| Furosemide | Furosemide | 152 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 147 | 32 |
| Omeprazole | Omeprazole | 144 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 21 |
| Lorazepam | Lorazepam | 138 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 34 |
| Tramadol Hcl | Tramadol Hcl | 127 | 36 |
| Baclofen | Baclofen | 121 | 35 |
| Eliquis | Apixaban | 101 | 17 |
| Alprazolam | Alprazolam | 97 | 15 |
| Ibuprofen | Ibuprofen | 92 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 25 |
| Pregabalin | Pregabalin | 92 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 19 |
| Trazodone Hcl | Trazodone Hcl | 88 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 19 |
| Mirtazapine | Mirtazapine | 84 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 35 |
| Famotidine | Famotidine | 70 | 20 |
| Diazepam | Diazepam | 67 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 27 |
| Clonazepam | Clonazepam | 65 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 13 |
| Jardiance | Empagliflozin | 63 | 16 |
| Simvastatin | Simvastatin | 63 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 21 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 59 | 25 |
| Potassium Chloride | Potassium Chloride | 56 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 12 |
| Celecoxib | Celecoxib | 51 | 18 |
| Donepezil Hcl | Donepezil Hcl | 51 | 13 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Carvedilol | Carvedilol | 45 | 15 |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 13 |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 41 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 16 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Nystatin | Nystatin | 31 | 15 |
| Ozempic | Semaglutide | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Methadone Hcl | Methadone Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Xtampza Er | Oxycodone Myristate | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 22 |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 12 |
| Glipizide | Glipizide | 23 | suppressed |
| Prednisone | Prednisone | 23 | 18 |
| Azithromycin | Azithromycin | 22 | 16 |
| Buprenorphine Hcl | Buprenorphine Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Dayvigo | Lemborexant | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Jatenzo | Testosterone Undecanoate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,576.25 · 56 records | Neurocrine BioSciences, Inc. | AUSTEDO XR, EPIDIOLEX, FANAPT, Fintepla, HETLIOZ, INGREZZA, JOURNAVX, Kerendia, MOUNJARO, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error